US 12,324,918 B2
Methods and systems for lead movement detection and response in DBS therapy
G. Karl Steinke, Valencia, CA (US); Manoj Vasantharaj, Valencia, CA (US); Raul Enrique Serrano Carmona, Venice, CA (US); and Mahsa Malekmohammadi, Sherman Oaks, CA (US)
Assigned to Boston Scientific Neuromodulation Corporation, Valencia, CA (US)
Filed by Boston Scientific Neuromodulation Corporation, Valencia, CA (US)
Filed on Sep. 11, 2023, as Appl. No. 18/464,902.
Application 18/464,902 is a continuation of application No. 17/653,816, filed on Mar. 7, 2022, granted, now 11,786,736.
Claims priority of provisional application 63/263,634, filed on Nov. 5, 2021.
Claims priority of provisional application 63/162,887, filed on Mar. 18, 2021.
Prior Publication US 2023/0414948 A1, Dec. 28, 2023
Int. Cl. A61N 1/36 (2006.01); A61B 5/00 (2006.01); A61B 5/06 (2006.01); A61B 5/377 (2021.01); A61N 1/05 (2006.01)
CPC A61N 1/3614 (2017.08) [A61N 1/0534 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method of programming stimulation for deep brain stimulation (DBS) to treat Parkinson's Disease (PD) in a patient having one or more electrode leads implantable in their brain, wherein each electrode lead comprises a plurality of electrode contacts, the method comprising:
receiving parameters specifying (1) a first stimulation location on the lead, and (2) a first one or more values for one or more features extracted from recorded first evoked potentials (EPs) evoked by stimulation at the first stimulation location, wherein the first stimulation location and the first one or more values were previously determined when the lead was implanted in the patient's brain,
providing a second stimulation to the patient's brain using the first stimulation location upon the lead,
recording second EPs evoked by the second stimulation,
extracting second one or more values for the one or more features of the second EPs,
comparing the first and second one or more values to determine whether to use the first stimulation location as an input for a lead optimization to program stimulation for the patient,
if it is determined to use the first stimulation location, inputting the first stimulation location into the lead optimization program,
if it is determined not to use the first stimulation location, inputting an alternative stimulation location into the lead optimization program,
using the lead optimization program to optimize therapeutic stimulation, wherein the therapeutic stimulation is configured to treat PD, and
providing the optimized stimulation to the patient.